- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
FDA Agrees to Review Rizatriptan Oral Film Formulation for Acute Migraine
Approval decision expected in February 2014 (June 18)
The FDA has accepted a new drug application (NDA) for RHB-103 (RedHill Biopharma/IntelGenz Corp.), an investigational oral thin-film formulation of the acute migraine drug rizatriptan.
The Prescription Drug User Fee Act (PDUFA) goal date — the targeted date for the FDA to complete its review of the NDA — was set for February 3, 2014.
RHB-103 is a proprietary oral thin-film formulation of rizatriptan benzoate, a 5-HT1 agonist and the active drug in Maxalt (Merck). The triptans are a class of molecules that constrict blood vessels in the brain to relieve swelling and other migraine symptoms.
According to the product’s developers, the RHB-103 thin film strip dissolves rapidly in the mouth, leading to the absorption of the drug through the gastrointestinal tract and into the bloodstream.
Source: RedHill Biopharma Ltd.; June 18, 2013.